Current perspectives on Stevens-Johnson syndrome and toxic epidermal necrolysis

M Lerch, C Mainetti, B Terziroli Beretta-Piccoli… - Clinical reviews in …, 2018 - Springer
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are considered a
delayed-type hypersensitivity reaction to drugs. They represent true medical emergencies …

Barriers to clinical adoption of pharmacogenomic testing in psychiatry: a critical analysis

CR Virelli, AG Mohiuddin, JL Kennedy - Translational psychiatry, 2021 - nature.com
Pharmacogenomics (PGx) is the study of genetic influences on an individual's response to
medications. Improvements in the quality and quantity of PGx research over the past two …

[HTML][HTML] Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis

A Hasegawa, R Abe - F1000Research, 2020 - ncbi.nlm.nih.gov
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening
diseases characterized by detachment of the epidermis and mucous membrane. SJS/TEN …

British Association of Dermatologists' guidelines for the management of Stevens–Johnson syndrome/toxic epidermal necrolysis in children and young people, 2018

T McPherson, LS Exton, S Biswas… - British Journal of …, 2019 - academic.oup.com
British Association of Dermatologists' guidelines for the management of Stevens–Johnson
syndrome/toxic epidermal necrolysis in children and young people, 2018 | British Journal of …

Translational pharmacogenomics: discovery, evidence synthesis and delivery of race‐conscious medicine

BH Davis, NA Limdi - Clinical Pharmacology & Therapeutics, 2021 - Wiley Online Library
Response to medications, the principal treatment modality for acute and chronic diseases, is
highly variable, with 40–70% of patients exhibiting lack of efficacy or adverse drug reactions …

Diagnostic test criteria for HLA genoty** to prevent drug hypersensitivity reactions: a systematic review of actionable HLA recommendations in CPIC and DPWG …

LEN Manson, JJ Swen, HJ Guchelaar - Frontiers in pharmacology, 2020 - frontiersin.org
Introduction Certain HLA variants are associated with an increased risk of hypersensitivity
reactions to specific drugs. Both the Clinical Pharmacogenetics Implementation Consortium …

Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN)

EC Kuijper, LE French, CP Tensen… - Journal of the …, 2020 - Wiley Online Library
The severe cutaneous adverse reaction epidermal necrolysis (EN) which includes toxic
epidermal necrolysis and the milder Stevens‐Johnson syndrome is characterized by …

Associations of HLA genetic variants with carbamazepine‐induced cutaneous adverse drug reactions: An updated meta‐analysis

M Biswas, M Ershadian, J Shobana… - Clinical and …, 2022 - Wiley Online Library
Aggregated risk of carbamazepine (CBZ)‐induced cutaneous adverse drug reactions
(cADRs) with different HLA variants are unclear and limited in terms of the power of studies …

[HTML][HTML] Carbamazepine therapy and HLA genotype

L Dean - 2018 - europepmc.org
Carbamazepine (brand names include Carbatrol, Epitol, Equetro, and Tegretol) is an
effective antiseizure drug that is often used as a first-line agent in the treatment of epilepsy …

Integrating real‐world data in cost‐effectiveness analysis of universal HLA‐B*15:02 screening in Malaysia

HY Chong, KS Lim, SL Fong… - British Journal of …, 2023 - Wiley Online Library
Aims Despite the availability of newer antiseizure medications, carbamazepine (CBZ)
remains the gold standard. However, patients of Asian ancestry are susceptible to CBZ …